



ISTITUTO DI RICERCHE
FARMACOLOGICHE
MARIO NEGRI · IRCCS

Ranica, October 5th, 2021

Title: "A phase II, randomized, double-blind, placebo-controlled Trial to evaluate the safety and efficacy of CEMDISIRAN (ALN-CC5) following withdrawal of chronic Eculizumab therapy in patients with Atypical HUS at high risk of recurrence"

Acronym: DANCE

EUDRACT N: 2018-004382-13

Sponsor: Istituto di Ricerche Farmacologiche Mario Negri IRCCS

On November 5, 2020, due to the lack of financial support from the Company, the study was withdrawn.

Your faithfully,

Prof. Giuseppe Remuzzi

Sede Legale
Mario Negri Milano

Via Mario Negri, 2 - 20156 Milano
Tel. +39 02 390141
mnegri@marionegri.it

Centro di Ricerche Cliniche
per le Malattie Rare "Aldo e Cele Daccò"
Villa Camozzi

Via G.B. Camozzi, 3 - 24020 Ranica (BG)
Tel. +39 035 45351
villacamozzi@marionegri.it

Centro Anna Maria Astori
Parco Scientifico Tecnologico
Kilometro Rosso

Via Stezzano, 87 - 24126 Bergamo
Tel. +39 035 42131
bergamo@marionegri.it

marionegri.it